University of Alabama Birmingham
Apolipoprotein E Mimetic Peptide Improves Hdl Functionality And Inhibits Atherosclerosis Progression In Mouse Models Of Atherosclerosis
Abstract
dc:description.abstractDespite major advances in diagnosis and treatment, coronary artery disease (CAD) is still the number one cause of morbidity and mortality in United States. An ideal treatment for lipid-mediated inflammatory disorders would not only reduce plasma cholesterol dramatically but also improve high density lipoproteins (HDL) function. Apolipoprotein E (apo E), a protein component of HDL and very low density lipoprotein (VLDL), is necessary for the receptor mediated hepatic uptake of apolipoprotein-B (apo B) containing remnant lipoproteins and also possesses strong anti-inflammatory properties. We hypothesized that a synthetic dual domain apo E mimetic peptide, Ac-hE18A-NH2 (a 28-residue peptide) containing receptor binding region (141-150) from human apo E covalently linked to a well-studied lipid binding amphipathic helical peptide18A will inhibit atherosclerosis and improve HDL due to its anti-inflammatory properties and its ability to clear atherogenic lipoproteins, analogous to full length apoE (299 amin oacids in length). Administration of Ac-hE18A-NH2 into dyslipidemic animal models resulted in a dramatic reduction in plasma cholesterol levels via binding to heparan sulfate proteoglycans (HSPG), while no reduction was seen in plasma cholesterol levels in animals injected with either saline or a control peptide (Ac-nhE18A-NH2 , obtained by covalently linking 151-160 region of apoE to 18A). Administration of Ac-hE18A-NH2 three times a week for six weeks to apo E null mice improved paraoxonase-1 (PON-1) activity, a marker for improved HDL function, and inhibited LDL-induced monocyte chemotaxis and atherosclerotic lesion progression. Ac-hE18A-NH2 was more effective than 4F, a well studied apolipoprotein A-I (apo A-I) mimetic peptide, in inhibiting atherosclerosis in an animal model. Recent investigations comparing this peptide Ac-hE18A-NH2 to the 18-residue single domain apoE mimetic peptide mR18L capable of reducing plasma cholesterol in LDL-R null mice fed a Western diet, showed while peptides were comparable in their ability to reduce plasma cholesterol; the peptide Ac-hE18A-NH2 was significantly more effective in reducing lesion. In conclusion, results of these investigations show that the 28 residue peptide Ac-hE18A-NH2 mimics apolipoprotein E in cholesterol reducing and anti-inflammatory properties and may be an ideal agent to treat lipid-mediated disorders worthy of clinical trials in humans.
Degree
thesis:*- Level thesis:degree_level
- Dissertation
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Nayyar, Gaurav
- Contributors dc:contributor
-
- G M Anatharamaiah
- David W Garber
- C Roger White
- Jose R Fernandez
- Yuchang Fu
- W Timothy Garvey
Subjects
dc:subject × 5Identifiers
dc:identifier.*- Repository record dc:identifier
- https://digitalcommons.library.uab.edu/etd-collection/2564